Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Dr. Arndt Schottelius
Chief Development Officer
Germany
MorphoSys AG (MOR) - developing innovate cancer treatment antibodies.
MorphoSys develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By applying its proprietary technologies, MorphoSys has become a leader in therapeutic antibodies, one of the fastest-growing drug classes in human health-care.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
<<   BACK   1 2 3 4 5 6 7 8 of 14   MORE   >> SHOW
  Select a title or search in slides to skip chapters
00:00
Dr. Arndt Schottelius, Antibodies , Morphosys: Optimizing Antibodies to Fight Cancer: MOR208 as a New Approach in B-cell Malignancies
00:30
Pipeline, antibody library HuCAL, Diagnostics, Financial Strength, Management Team, MorphoSys: Overview
01:25
Sales, Antibody Product Sales, biological drugs, toxicity, indications, generics, Why Antibodies?
02:41
Naked Antibodies, Antibodies with optimized Fc part, Bi-/Tri-functional Antibodies , Approaches to
03:47
MOR208 (XmAb®5574), B-cell Malignancies, CD19, Xencor, , MOR208 (XmAb(R) 5574) as a New Approach in B-cell Malignancies
04:40
B Cell Malignancies, leukemias, lymphomas, acute lymphoblastic, sales , Some Facts About B Cell Malignancies
06:00
Anti-tumor Mechanisms, IgG – Fc Receptor Interactions, mAb activity, NK cell, Enhanced ADCC, phagocytosis by macrophages, Anti-tumor Mechanisms are Mediated by IgG - Fc Receptor Interactions
07:18
B-cell Malignancies, Anti-CD19 Antibodies, clinical data, NHL, ALL, B-cell depletion in lymphoma , Anti-CD19 Antibodies Hold Promise for the Treatment of B-cell Malignancies
08:05
Efficacy, FcyR, xenograft, Ramos, , Efficacy Against Established Tumors is FcyR-Dependent and Enhanced by Fc Engineering
09:04
MOR208 XmAb5574, Cynomolgus Monkeys, MOR208/XmAb5574 Showed Rapid and Sustained Depletion of B cells in Cynomolgus Monkeys
09:46
MOR208 XmAb5574, Potent ADCC, Patient-Derived B-CLL Cells, MOR208/XmAb5574 Induces Potent ADCC Against Patient-Derived B-CLL Cells
10:54
MOR208, CD19 Antibody, safety, Fc domain modification of MOR208 , MOR208 is Competitive in the CD19 Antibody Space
11:50
MOR208 – Ongoing Phase 1 Trial, Design, Population, Clinical Data, trials , MOR208 - Ongoing Phase 1 Trial
12:48
Antibody Pipeline, programs, Novartis, Roche, Pfizer , MorphoSys's Antibody Pipeline - One of the Broadest in the Industry
14:57
Contact, Thank You